MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
03/13/17MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
NASDAQ GS | MYOK (Common Stock)
$13.05 + 0.15
04/28/174:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.